Bioavailability of Different Formulations of Metformin Hydrochloride in Healthy Volunteers: a Comparative Study
Keywords:Therapeutic equivalency, biological availability, clinical trial, metformin
Objective: To assess the bioavailability of a formulation of metformin hydrochloride 850 mg coated tablets as test, compared to a reference product with the same dosage form, in healthy volunteers of both genders. Method: This clinical trial was designed as randomised, comparative, single-dose, open-label, two-period, two-sequence, crossover study under fasting conditions. 28 healthy volunteers (fourteen men and fourteen women) took part in the study. The 850 mg coated tablets formulations were administered in a single dose orally. Blood samples were obtained prior to dosing and at 30 min, 1, 1:20; 1:40, 2, 2:20, 2:40; 3, 3:20, 3:40 4, 4:30, 5, 6, 8, 12, 16, 24 and 36 hours after drug administration with an one week washout period. Plasmatic concentrations of metformin were measured by specific and validated analytical methods based on high-performance liquid chromatography coupled to mass spectrometry (HPLC/MS). The pharmacokinetics parameter AUC0-36h, AUC0-âˆž and Cmax were tested for bioequivalence after log transformation of data and ratios of Tmax were evaluated non parametrically. Findings: Data from this study showed that the test and the reference formulation presented similar results, within the acceptance range (80-125%) for AUC0-âˆž (area under curve) and Cmax (maximum serum concentration of the drug) parameters, satisfying the bioequivalence criteria of the Brazilian Health Surveillance Agency and FDA. Conclusion: These results indicate that the two formulations of metformin hydrochloride 850 mg coated tablets are bioequivalent, thus, it will be possible to ensure interchangeability between them, which can generate market competition and better access to this treatment.
Ashcroft FM, Rorsman P. Diabetes mellitus and the beta cell: the last ten years. Cell. 2012;148:1160-71. Available from: http://dx.doi.org/10.1016/j.cell.2012.02.010
Rodrigues Neto EM, Marques LARV, Ferreira MAD, Lobo PLD, GirÃ£o JÃºnior FJ, CamarÃ£o GC, et al. Metformina: uma revisÃ£o da literatura. SaÃºde e Pesquisa. 2015;8:355-62. Available from: http://dx.doi.org/10.17765/1983-1870.2015v8n2p355-362
Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med. 2008;168:2088-94. Available from: https://dx.doi.org/10.1001%2Farchinte.168.19.2088
Van Der Meersch A, Dechartres A, Ravaud P. Quality of reporting of bioequivalence trials comparing generic to brand name drugs: a methodological systematic review. PLoS ONE. 2011;6:e23611. Available from: http://dx.doi.org/10.1371/journal.pone.0023611
Robert F, Fendri S, Hary L, Lacroix C, AndrÃ©jak M, Lalau JD. Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects. Diabetes Metab. 2003;29:279-83. Available from: http://www.em-consulte.com/en/article/80210
Hu LD, Liu Y, Tang X, Zhang Q. Preparation and in vitro/in vivo evaluation of sustained-release metformin hydrochloride pellets. Eur J Pharm Biopharm. 2006;64:185-92. Available from: http://dx.doi.org/10.1016/j.ejpb.2006.04.004
Al Hawari S, AlGaai E, Yusuf A, Abdelgaleel A, Hammami MM. Bioequivalence study of two metformin formulations. Arzneimittelforschung. 2007;57:192-5. Available from: http://dx.doi.org/10.1055/s-0031-1296605
Porta V, Schramm SG, Kano KE, Koono EE, Armando YP, Fukuda K, Serra CHR. HPLC-UV determination of metformin in human plasma for application in pharmacokinetics and bioequivalence studies. J Pharm Biomed Anal. 2008;46:143-7. Available from: http://dx.doi.org/10.1016/j.jpba.2007.10.007
Souza FC, Marques EB, Scaramello CBV. VariaÃ§Ãµes interindividuais na farmacocinÃ©tica clÃnica de cardiotÃ´nicos. Rev Bras Cardiol. 2013;26:213-20. Available from: http://www.rbconline.org.br/artigo/variacoes-interindividuais-na-farmacocinetica-clinica-de-cardiotonicos/
Costa VM, Bastos ML, Carvalho F. GÃ©nero masculino vs feminino: factor relevante para as respostas farmacolÃ³gicas e efeitos adversos de fÃ¡rmacos? Acta FarmacÃªutica Portuguesa. 2011;1:55-64. Available from: http://www.actafarmaceuticaportuguesa.com/index.php/afp/article/view/32
Motta ELA, Domingues TS, Soares JÃºnior JM. O uso de sensibilizadores de insulina no tratamento de infertilidade em pacientes com sÃndrome dos ovÃ¡rios policÃsticos (SOP). Rev Bras Ginecol Obstet, 2012;34:99-101. Available from: http://dx.doi.org/10.1590/S0100-72032012000300001
Campo-Arias A, Herazo YE. Cefalea como sÃntoma de abstinencia a la cafeÃna: un estudio poblacional. Rev. fac. med. 2008;16:176-83. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0121-52562008000200005&lng=en
Cruzado L, SÃ¡nchez-fernÃ¡ndez M, Cortez-Vergara C, Rojas-Rojas G. ManÃa inducida por bebidas energÃ©ticas con alto contenido de cafeÃna. Actas Esp Psiquiatr. 2014;42:259-66. Available from: http://actaspsiquiatria.es/repositorio/16/91/ESP/16-91-ESP-259-262-556333.pdf
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under aÂ Creative Commons Attribution LicenseÂ that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open AccessÂ and Benefits of Publishing Open Access).